Coverage / C43 / Trade Card

C43

Cosmo Pharmaceuticals NV

OPPORTUNISTIC BUY 2026-08-01 Updated today EUR 66.20 Healthcare - Drug Manufacturers - Specialty & GenericAWAIT ENTRY
59

Position levels

Currenttoday
EUR 66.20
Buy <=wait / entry
EUR 57.33
Trim >=take some off
EUR 72.00
Thesis breakRecurring revenue growth decelerating below 5% year-on-year for two consecutive ...
-

Scenario-weighted conviction

ProbabilityScoreContribution
Bull case25%100 / 10025.0
Base case50%62 / 10031.0
Bear case25%10 / 1002.5
Weighted conviction59 / 100 - OPPORTUNISTIC BUY

Top risks

  • 2025 revenue of EUR 104.2 million with 85% recurring revenues and +15% YoY growth
  • 2026 guidance for continued double-digit recurring revenue and EBITDA growth to EUR 10.5-13.5 million
  • Proposed EUR 2.10 per share dividend with year-end cash expected at approximately EUR 200 million
Read full report →

Research is for informational purposes only. Not financial advice. All analysis reflects the date of publication.